Immunwork’s Next-Generation Long-Acting Octreotide Analog TE-8214 Published in International Journal

By /

T-E Pharma’s subsidiary, Immunwork, Inc., recently announced that the latest research findings on its next-generation long-acting octreotide analog TE-8214 have been officially published in the internationally recognized journal Frontiers in Endocrinology. The paper is entitled “A Long-Acting Octreotide Analog Formed by Conjugation with a Peptide Linker Modified with Two Fatty Acids.”。

    Frontiers in Endocrinology is an internationally recognized, peer-reviewed journal with a strong focus on endocrinology and metabolic diseases, covering basic, translational, and clinical research in endocrinology, metabolism, and related disorders. The publication presents the innovative drug design and nonclinical findings of TE-8214, together with clinical findings from its first-in-human study, including safety, tolerability, and therapeutic potential, providing an important scientific foundation for its continued clinical development.。

Innovative Fatty Acid Bundle Platform Enables Long-Acting Octreotide with a Novel Approach to Sustained Drug Action

    TE-8214 is a long-acting octreotide analog developed using Immunwork’s proprietary “Fatty Acid Bundle Platform”. Through an innovative molecular design, the fatty acid bundle is conjugated to octreotide to extend its duration of action while maintaining good aqueous solubility.

    Unlike conventional long-acting octreotide formulations that rely on high-viscosity microparticle or gel-based depot systems, TE-8214 achieves prolonged activity through its molecular design and can be formulated as an aqueous subcutaneous injection suitable for fine-gauge needles. This approach may offer a more convenient and patient-friendly alternative to conventional depot formulations.

Phase 1 Clinical Data Support Favorable Safety and Tolerability and Demonstrate Therapeutic Potential

    The Phase 1 clinical trial of TE-8214 was completed in Australia, demonstrating a favorable safety and tolerability profile. Treatment-related adverse events were primarily mild gastrointestinal symptoms, with no drug-related serious adverse events observed. TE-8214 also showed favorable injection-site tolerability, with no significant injection-site pain or nodules reported.

    In addition to safety and injection-site tolerability, clear pharmacodynamic activity was observed in the Phase 1 study. Among the 12 subjects receiving TE-8214 at the higher doses of 2 mg and 4 mg, 10 subjects (83%) achieved a reduction of more than 20% in insulin-like growth factor-1 (IGF-1). These findings are consistent with the long-acting pharmacological activity observed in previous nonclinical studies. Nonclinical studies demonstrated that TE-8214 could sustain the suppression of biomarkers including serotonin, growth hormone (GH), and IGF-1 across different animal models, further supporting its long-acting pharmacological profile.

From Innovative Drug Design to Clinical Validation: Establishing a Scientific Foundation for Further Development

    The publication of these findings in Frontiers in Endocrinology marks an important milestone in the development of TE-8214, demonstrating the progression of the program from early-stage technology validation to clinical development supported by human clinical data. The study has also undergone international peer review, providing an important scientific foundation for the continued clinical development of TE-8214.

Immunwork stated that the key differentiation of TE-8214 lies not only in extending the duration of action of octreotide, but also in its distinct drug design and formulation strategy compared with conventional sustained-release formulations. The approach is designed to combine long-acting activity, the convenience of aqueous subcutaneous administration, and favorable injection-site tolerability.

Phase 2 Clinical Trial Planned to Launch in Australia and Taiwan, Advancing Global Clinical Development

    TE-8214 is primarily being developed for the treatment of acromegaly and neuroendocrine tumors (NETs). Although octreotide and other somatostatin analogs are widely used in the treatment of these diseases, there remains an unmet need for more convenient long-acting formulations with improved formulation characteristics and injection experience.

The Phase 2 clinical trial of TE-8214 is currently planned to initiate in Australia and Taiwan in Q4 2026, further evaluating its efficacy, safety, and dosing strategy in patient populations.

Immunwork will continue to advance the clinical development of TE-8214 while actively exploring international collaboration and global commercialization opportunities. Through its innovative long-acting drug design and aqueous subcutaneous formulation strategy, Immunwork aims to develop TE-8214 as a more convenient and differentiated treatment option for patients worldwide.

References and Related Coverage of TE-8214:

Scroll to Top